United States v. Jeffrey R. Green

818 F.3d 1258, 2016 U.S. App. LEXIS 6347, 2016 WL 1382578
CourtCourt of Appeals for the Eleventh Circuit
DecidedApril 7, 2016
Docket15-10270
StatusPublished
Cited by13 cases

This text of 818 F.3d 1258 (United States v. Jeffrey R. Green) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Jeffrey R. Green, 818 F.3d 1258, 2016 U.S. App. LEXIS 6347, 2016 WL 1382578 (11th Cir. 2016).

Opinion

HULL, Circuit Judge:

After a jury trial, defendants Jeffrey Green and Karen Hebble were each convicted of one count of conspiracy to distribute controlled substances, in violation of 21 U.S.C. §§ 841(a)(1), (b)(1)(C), and 846; and one count of conspiracy to commit money laundering, in violation of 18 U.S.C. § 1956(h). As objects of the latter conspiracy, defendants Green and Hebble together were convicted of two ¡counts of money laundering and defendant Green was separately convicted of four additional counts of money laundering, all in violation of 18 U.S.C. §§ 1957 and 2. After review and with the benefit of oral argument, we affirm.

I. PROCEDURAL HISTORY

On July 24, 2013, a grand jury returned a superseding indictment against the defendants charging them with (1) conspira^ cy to distribute controlled substances, (2) conspiracy to commit money laundering of the proceeds of that illegal distribution, and (3) multiple money laundering counts for individual'monetary'transactions involving those drug distribution proceeds. The indictment also sought forfeiture of various assets.

Before trial, the defendants filed a joint motion to sever with each offering independent reasons for severance. Specifically, defendant Hebble argued that if the court severed their trials and if Green were tried first, then Green would provide exculpatory testimony on Hebble’s behalf at her trial. The district court denied the defendants’ motion, rejecting both defendants’ independent arguments. Defendant Hebble renewed her motion to sever at the close of the government’s case, and the district court again denied her motion.

The jury’s verdict convicted the defendants on all counts. Post-trial, the defendants renewed their motion for judgment of acquittal, which they had timely made at the close of the government’s case. The district court denied the motion.

The defendants subsequently moved for a new trial or alternatively for dismissal' on the basis that the government' had én-gaged in “selective prosecution,” in violation of their Fifth Amendment Due Process rights. The district court denied the motion and rejected the selective prosecution claim as improperly raised and untimely.

On appeal, the defendants challenge the sufficiency of the evidence supporting their convictions as well as the district court’s rulings denying their selective prosecution claim and defendant Hebble’s motion for severance. Because the defendants challenge the sufficiency of the evidence, we first review the evidence presented at trial.

*1262 II. TRIAL EVIDENCE

Defendants Green and Hebble ran two businesses, the Gulf Coast Medical Pharmacy and the Gulf Coast Infusion Center (collectively “Gulf Coast”), out of a small suite in a medical building near the Gulf Coast Medical Hospital in Lee County, Florida. 1 Defendant Green owned and operated Gulf Coast. Green was also registered as a pharmacist technician under Florida law, but he was not a pharmacist himself. Green’s then-fiancée; defendant Hebble, functioned as the store manager for the two businesses.

The lion’s share of Gulf Coast’s business consisted of oxycodone sales, a Schedule II narcotic and controlled-substance with a high degree of addiction and abuse potential. In 2009, Gulf Coast purchased 475,-900 pills of oxycodone from pharmaceutical distributors for retail sale. In 2010, that figure rose to 1,486,200 pills. By 2011, Gulf Coast purchased 2,059,700 pills. 2 By comparison, from 2009 through 2011, all other independent pharmacies within Gulf Coast’s 33912 zip code area (about ten total) collectively purchased one-third the volume of oxycodone as Gulf Coast purchased. The average purchase volume of oxycodone for pharmacies nationwide in 2010 was approximately 69,000 pills.

Gulf Coast proved to be very lucrative, Gulf Coast’s policy was that, while customers could purchase other medications using insurance, customers could not use insurance to purchase oxycodone; they had to pay in full with .cash, credit card, or debit card. Most paid in cash. Gulf Coast charged between $250 and $500 for a typical oxycodone prescription. . For Roxicodone, a more expensive name-brand version of oxycodone, Gulf Coast charged between $800 and $900 per prescription. In 2011 alone, the pharmacy filled 15,400 oxycodone prescriptions. The result: Gulf Coast frequently brought in $15,000 to $28,000 per day per register in cash-only sales.

Gulf Coast maintained multiple bank accounts over which defendants Green and Hebble were co-owners and co-signers. From January 2010 through October 2011, over $3,500,000 in cash was deposited into just one of those accounts alone. Among other things, Green and Hebble used this money to pay their mortgage and later to fully pay off their home, pay off student loans, pay for a $25,000 diamond ring, and pay Green a $100,000 “getting married bonus.”

But on’November 4, 2011, all this came to a half when the Drug Enforcement Agency (“DEA”) raided Gulf Coast and seized evidence related to the defendants’ illegal drug distribution conspiracy. We recount the details of that conspiracy.

A. Central Florida’s Underground Oxy-codone Market

At trial, the government presented numerous witnesses who described how the Central Florida underground oxycodone market worked. The system operated through the participation of a number of players, including drug dealers, fake patients, and cooperating doctors and clinics. One other key participant in the market was pharmacies, which ultimately supplied *1263 the controlled substances that would later be sold on the streets.

First, drug dealers, known as “sponsors,” recruited and paid drug addicts or people otherwise desperate for money, called “spuds” or “skidoodies,” to pose as fake patients. Having recruited a group of fake patients, drug dealers would then shuttle them to and from several clinics a day with the goal of obtaining multiple oxycodone prescriptions for each fake patient.

Drug dealers targeted clinics that were willing to write numerous prescriptions for controlled substances for patients who had no medical need for these drugs. Participating doctors frequently performed superficial examinations on fake, patients, sometimes only lasting a few minutes. Some clinics had superficial drug screening procedures in place. Often, if a fake patient were likely to fail a drug test while at the clinic, a drug dealer or fake patient could pay extra to avoid a failed drug test. Some clinics required that the fake patients have MRIs before they would write prescriptions; in such cases, the drug dealers would first take the fake patients to radiology clinics that were willing to create MRIs falsely showing back injuries before taking the fake patients to get their prescriptions.

.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Tonya Robinson
Seventh Circuit, 2025
United States v. Albert Smith
Seventh Circuit, 2025
United States v. Rudolph
Tenth Circuit, 2025
United States v. Reginald Graham
123 F.4th 1197 (Eleventh Circuit, 2024)
United States v. James Dixon
901 F.3d 1322 (Eleventh Circuit, 2018)
United States v. Thomas S. Jackson
688 F. App'x 685 (Eleventh Circuit, 2017)
United States v. Travis Edward Gross
661 F. App'x 1007 (Eleventh Circuit, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
818 F.3d 1258, 2016 U.S. App. LEXIS 6347, 2016 WL 1382578, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-jeffrey-r-green-ca11-2016.